Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis.

Pharmacoecon Open · 2018 · PMC6103924 · PMID 29623628

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Treatment Effectiveness A recent Cochrane review [ 36 ] reported the relative risk (RR) of progression to dementia as 0.84 (95% CI 0.70–1.02) over 3 years (although effects for year 1 and year 3 were borderline significant) in MCI patients treated with a ChEI.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.